plaque psoriasis

Combination topical treatment reduces psoriasis severityThe fixed combination of halobetasol and tazarotene topicals significantly reduced the severity of localized disease with a favorable safety profile, shows a study published in the Journal of the American Academy of Dermatology.
Biosimilars safety performance in psoriasisA study that compares the safety, efficacy and drug survival of biologics to biosimilars, finds that switching to a biosimilar had no significant impact on drug survival or safe
Moderate plaque psoriasis may resolve with apremilastWhile there are biologics and systemic agents designed to control the severe form of plaque psoriasis, few treatments work as well in moderate plaque psoriasis. Apremilast may be a game changer.
FDA approves a new, more powerful psoriasis drug“As we move toward finding a cure for psoriasis, what we are looking for are high performance drugs that provide durable response in between treatments and that lend themselves to patient compliance,” says Dr. George Martin.
Neurologic changes that stem from biologic therapyPhysicians should be aware of the warning signs that a biologic agent could be to blame when patients experience subacute or rapidly progressive neurologic changes, researchers say.
Diabetes risk in psoriasis increases with disease severityIn severe psoriasis, every 10 percent increase in affected body surface area increases diabetes risk by 20 percent, researchers find.
Ustekinumab shows promise for reducing psoriasis-associated cardiovascular comorbidityInitial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.
The evolution of psoriasis from skin to heart diseaseMounting clinical evidence points to a need for tighter disease control in psoriasis patients, says Dr. Alexander Egeberg.
FDA clears new drug application for topical psoriasis treatmentThe Food and Drug Administration accepted a new drug application for IDP-118 lotion (halobetasol propionate and tazarotene, Ortho Dermatologics), for the topical treatment of plaque psoriasis.
The top 25 psoriasis authorsIn 2018 at just five days into the New Year, a search of PubMed revealed 86 new psoriasis studies. So, who is leading the pack?